THE COST-EFFECTIVENESS OF SECOND-LINE CRIZOTINIB IN EML4-ALK REARRANGED ADVANCED NON-SMALL CELL LUNG CANCER

被引：0
|
作者：
Graham, Donna M. [1 ]
Djalalov, Sandjar [2 ]
Beca, Jaclyn [2 ]
Hoch, Jeffrey [3 ]
Tsao, Ming S. [4 ]
Cutz, Jc [5 ]
Leighl, Natasha [1 ]
机构：
[1] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, East Melbourne, Vic, Australia
[2] Canc Care Ontario, Pharmacoecon Res Unit, Toronto, ON, Canada
[3] Canc Care Ontarior Pharmacoecon Unit, Toronto, ON, Canada
[4] Princess Margaret Canc Ctr, Dept Pathol, East Melbourne, Vic, Australia
[5] McMaster Univ, Hamilton, ON L8S 4L8, Canada
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
cost-effectiveness; ALK-rearrangement; Crizotinib; advanced non-small cell lung cancer;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.24-037
引用
收藏
页码：S1317 / S1318
页数：2
相关论文
共 50 条
  • [41] ALK Inhibitors Do Not Increase Sensitivity to Radiation in EML4-ALK Non-small Cell Lung Cancer
    Fleschutz, Kathrin
    Walter, Lisa
    Leistner, Rumo
    Heinzerling, Lucie
    ANTICANCER RESEARCH, 2020, 40 (09) : 4937 - 4946
  • [42] Cost-effectiveness of pembrolizumab versus docetaxel as second-line treatment of non-small cell lung cancer in China
    Shi, Yafei
    Chen, Wei
    Zhang, Yujun
    Bo, Mingming
    Li, Chunyu
    Zhang, Mingyu
    Li, Guohui
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (18)
  • [43] Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada
    Beca, Jaclyn M.
    Walsh, Shaun
    Raza, Kaiwan
    Hubay, Stacey
    Robinson, Andrew
    Mow, Elena
    Keech, James
    Chan, Kelvin K. W.
    BMC CANCER, 2021, 21 (01)
  • [44] Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada
    Jaclyn M. Beca
    Shaun Walsh
    Kaiwan Raza
    Stacey Hubay
    Andrew Robinson
    Elena Mow
    James Keech
    Kelvin K. W. Chan
    BMC Cancer, 21
  • [45] Optic Neuropathy and Blindness Associated With Crizotinib for Non-Small-Cell Lung Cancer With EML4-ALK Translocation
    Chun, Stephen G.
    Iyengar, Puneeth
    Gerber, David E.
    Hogan, Robert N.
    Timmerman, Robert D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (05) : E26 - E27
  • [46] Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China
    Guan, Haijing
    Liu, Gordon
    Xie, Feng
    Sheng, Yanan
    Shi, Luwen
    CLINICAL THERAPEUTICS, 2019, 41 (11) : 2308 - 2320
  • [47] Cost-effectiveness of trastuzumab deruxtecan as a second-line treatment for HER2-mutant advanced non-small cell lung cancer
    Cai, Qi
    You, Shuhui
    Huang, Jinglong
    Gong, Caifeng
    Zhang, Wen
    Zhou, Aiping
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2025, 21 (01)
  • [48] COST-EFFECTIVENESS OF CRIZOTINIB FOR FIRST-LINE TREATMENT IN NON-SMALL CELL LUNG CANCER IN ECUADOR
    Salcedo, E.
    Freire, V
    Cabezas, M.
    Albert, A.
    VALUE IN HEALTH, 2018, 21 : S32 - S32
  • [49] EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations
    Erik Thunnissen
    Lukas Bubendorf
    Manfred Dietel
    Göran Elmberger
    Keith Kerr
    Fernando Lopez-Rios
    Holger Moch
    Wlodzimierz Olszewski
    Patrick Pauwels
    Frédérique Penault-Llorca
    Giulio Rossi
    Virchows Archiv, 2012, 461 : 245 - 257
  • [50] SECOND-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER
    Cullen, M.
    LUNG CANCER, 2009, 64 : S13 - S13
12345